
#### MARKET ACCESS REPORT Jan-April 2024



9

OMPs have

in Spain

obtained National Code

reimbursed by the

%

2021

**Annual Average** 

2020

51%

2022

Not reimbursed by

Under study or without reimbursing

**%**9


2024\*

3%

2023

### New **orphan**

2



designations in

the **EU** 

## Jan-April 2024\* OMPs REIMBURSED BY THERAPEUTICAL AREA OMPs are currently

8 %


14 %

3%

2021

Annual Average

2020



**21%** 

2024\*

Nervous system


#### → AVERAGE WAITING TIME

3%

2022

53%

2023





NOT REIMBURSED IN SPAIN

MONTHS BETWEEN NC AND INCORPORATION INTO THE NHS

## 43

Orphan Medicinal Products with NC not reimbursed by





OMPs with MA without NC

14%

2024\*

2023

9 %


## 15% 16% 16%

2021

WAITING TIME SINCE MA

2020

% OMPs WITH MA WITHOUT NC



2022



Advanced Academic Therapies

Without NC

15

With NC

Reimbursed by the NHS

reimbursed by the NHS

Not

NHS

/

With unfavorable resolution

Under study or without request for reimbursing

16

Advanced Therapies with OD and MA\*\*

**ADVANCED THERAPIES** 

WITH ORPHAN DESIGNATION

# → ADVANCED THERAPIES

MA



NC

Note: for the preparation of this report it has not been possible to take into account drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data were not available.

\*Aggregated data as of April 30, 2024.

\*\*The 16 Advanced Therapies with OD and MA would be included in the total of 202 MMH with OD and in the 149 MMH with MA, as they are TTAAs with trade name.

The sources used for this report are the European Medicines Agency (EMA), the Community Register of Orphan Medicinal Products, the Spanish Agency for medicinal products and Health Products (AEMPS) and the Ministry of Health.